<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6838050</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">31700126</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">6838050</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">52757</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1038/s41598-019-52757-7</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographics, clinical and MRI data of the entire cohort of patients with MS and identified subgroups, as well as healthy controls.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Demographics, clinical and MRI data of the entire cohort of patients with MS and identified subgroups, as well as healthy controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>MS</th><th>WMD</th><th>GMD</th><th>HC</th><th><italic>p</italic></th><th><italic>p</italic></th></tr><tr><th>180</th><th>37 (21%)</th><th>37 (21%)</th><th>37</th><th>WMD vs GMD</th><th>WMD vs GMD vs HC</th></tr></thead><tbody><tr><td>sex (f)</td><td>114 (63%)</td><td>30 (81%)</td><td>20 (54%)</td><td>13 (35%)</td><td>0.024</td><td>0.001</td></tr><tr><td>Age, years</td><td>35.9 (9.8)</td><td>31.8 (6.9)</td><td>39.1 (9.9)</td><td>35.8 (7.9)*</td><td>0.001</td><td>0.001</td></tr><tr><td>EDSS</td><td>1.0 (2.1)</td><td>1.0 (1.9)</td><td>1.5 (1.8)</td><td>—</td><td>0.312</td><td/></tr><tr><td>Min-Max</td><td>0–6.0</td><td>0–4.0</td><td>0–5.5</td><td/><td/><td/></tr><tr><td>DD</td><td>5.0 (8.0)</td><td>5.5 (8.0)</td><td>3.5 (9.0)</td><td>—</td><td>0.969</td><td/></tr><tr><td>DMT</td><td>67 (37%)</td><td>12 (32%)</td><td>22 (59%)</td><td>—</td><td>0.062</td><td/></tr><tr><td>Clinical phenotype</td><td/><td/><td/><td>—</td><td>0.472</td><td/></tr><tr><td>CIS</td><td>61 (34%)</td><td>12 (32%)</td><td>13 (35%)</td><td/><td/><td/></tr><tr><td>RRMS</td><td>114 (63%)</td><td>24 (65%)</td><td>24 (65%)</td><td/><td/><td/></tr><tr><td>SPMS</td><td>5 (3%)</td><td>1 (3%)</td><td/><td/><td/><td/></tr><tr><td>NBV cm³</td><td>1516.2 (74.0)</td><td>1564.9 (36.1)</td><td>1473.6 (41.1)</td><td>1567.7 (71.8)</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>T2-LL cm³</td><td>16.9 (15.6)</td><td>22.6 (11.6)</td><td>7.2 (2.8)</td><td>—</td><td>&lt;0.0001</td><td/></tr></tbody></table><table-wrap-foot><p>Nominal data (sex) is shown in number of patients (N) and percentage (%). For continuous variables (age), mean and standard deviation (SD) are presented and for non-parametric data (EDSS, DD), median and interquartile range (IQR) are shown. CIS = clinically isolated syndrome, EDSS = Expanded Disability Status Scale, DD = disease duration, DMT = patients on disease modifying treatment; f = female, GMD = predominately grey matter damage group,HC = healthy controls, NBV = normalized brain volume; T2-LL = T2-lesion load; RRMS = relapsing-remitting MS, SPMS = secondary progressive MS, WMD = predominately white matter damage group.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographics, clinical and MRI data of the entire cohort of patients with MS and identified subgroups, as well as healthy controls.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>MS</th><th>WMD</th><th>GMD</th><th>HC</th><th>p</th><th>p</th></tr><tr><th>180</th><th>37 (21%)</th><th>37 (21%)</th><th>37</th><th>WMD vs GMD</th><th>WMD vs GMD vs HC</th></tr></thead><tbody><tr><td>sex (f)</td><td>114 (63%)</td><td>30 (81%)</td><td>20 (54%)</td><td>13 (35%)</td><td>0.024</td><td>0.001</td></tr><tr><td>Age, years</td><td>35.9 (9.8)</td><td>31.8 (6.9)</td><td>39.1 (9.9)</td><td>35.8 (7.9)*</td><td>0.001</td><td>0.001</td></tr><tr><td>EDSS</td><td>1.0 (2.1)</td><td>1.0 (1.9)</td><td>1.5 (1.8)</td><td>—</td><td>0.312</td><td/></tr><tr><td>Min-Max</td><td>0–6.0</td><td>0–4.0</td><td>0–5.5</td><td/><td/><td/></tr><tr><td>DD</td><td>5.0 (8.0)</td><td>5.5 (8.0)</td><td>3.5 (9.0)</td><td>—</td><td>0.969</td><td/></tr><tr><td>DMT</td><td>67 (37%)</td><td>12 (32%)</td><td>22 (59%)</td><td>—</td><td>0.062</td><td/></tr><tr><td>Clinical phenotype</td><td/><td/><td/><td>—</td><td>0.472</td><td/></tr><tr><td>CIS</td><td>61 (34%)</td><td>12 (32%)</td><td>13 (35%)</td><td/><td/><td/></tr><tr><td>RRMS</td><td>114 (63%)</td><td>24 (65%)</td><td>24 (65%)</td><td/><td/><td/></tr><tr><td>SPMS</td><td>5 (3%)</td><td>1 (3%)</td><td/><td/><td/><td/></tr><tr><td>NBV cm³</td><td>1516.2 (74.0)</td><td>1564.9 (36.1)</td><td>1473.6 (41.1)</td><td>1567.7 (71.8)</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>T2-LL cm³</td><td>16.9 (15.6)</td><td>22.6 (11.6)</td><td>7.2 (2.8)</td><td>—</td><td>&lt;0.0001</td><td/></tr></tbody></table></div>Nominal data (sex) is shown in number of patients (N) and percentage (%). For continuous variables (age), mean and standard deviation (SD) are presented and for non-parametric data (EDSS, DD), median and interquartile range (IQR) are shown. CIS = clinically isolated syndrome, EDSS = Expanded Disability Status Scale, DD = disease duration, DMT = patients on disease modifying treatment; f = female, GMD = predominately grey matter damage group,HC = healthy controls, NBV = normalized brain volume; T2-LL = T2-lesion load; RRMS = relapsing-remitting MS, SPMS = secondary progressive MS, WMD = predominately white matter damage group.</transformed-table></extracted-table></extracted-tables-set>